Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Springerplus|January 24, 2014
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHLKarin Hohloch, Carsten Zwick, Marita Ziepert, et al.
BMC Cancer|July 23, 2024
Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trialMeinolf Karthaus, Volker Heinemann, Jorge Riera-Knorrenschild, et al.
BMC Palliative Care|January 16, 2026
Palliative care interventions and outcome in patients with glioblastoma - a retrospective, single-center studyLisa-Marie Lind, Anna Fischl, Elisabeth Goettl, et al.
Cancer Treatment Reviews|April 3, 2007
High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysisAlexander Greb, Julia Bohlius, Sven Trelle, et al.
The Lancet. Oncology|December 15, 2015
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trialMathias Rummel, Ulrich Kaiser, Christina Balser, et al.
Cancer Medicine|February 11, 2022
Causes of mortality in elderly UICC stage III colon cancer (CC) patients--Tumor-related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registryStefanie Nöpel-Dünnebacke, Hendrick Jütte, Robin Denz, et al.
International Journal of Cancer|December 13, 2025
Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)Thorsten O Goetze, Salah-Eddin Al-Batran, Ruediger Liersch, et al.
Cancer Investigation|September 20, 2006
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaUlrich J M Mey, Katjana S Orlopp, Dimitri Flieger, et al.
Lancet (London, England)|February 26, 2013
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialMathias J Rummel, Norbert Niederle, Georg Maschmeyer, et al.
The European Respiratory Journal|September 30, 2022
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registryMartin Metzenmacher, Frank Griesinger, Horst-Dieter Hummel, et al.
Pageof 7